Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T in Relapsed/Refractory Multiple Myeloma
NCT04186052Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple myeloma (MM), sponsored by PersonGen BioTherapeutics. Primary endpoint: Incidence of Adverse Events or Serious Adverse Events of Grade 3 or Higher at 12 weeks. Status: unknown.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04186052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186052.